Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: technical recommendations

J Vasc Interv Radiol. 2014 Mar;25(3):365-9. doi: 10.1016/j.jvir.2013.11.027.

Abstract

Transcatheter hepatic arterial administration of irinotecan-loaded drug-eluting beads (DEBIRI) is used to treat liver-only or liver-dominant metastatic disease from colorectal cancer (CRC). Eligibility for DEBIRI should be established in each individual patient by a multidisciplinary team based on comprehensive clinical, imaging, and laboratory assessment. Standardization of DEBIRI technique and protocols would be expected to lead to improved efficacy and safety. The present article provides a set of technical recommendations for the use of DEBIRI in the treatment of hepatic CRC metastases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives*
  • Chemoembolization, Therapeutic / standards*
  • Colorectal Neoplasms / therapy*
  • Delayed-Action Preparations / administration & dosage*
  • Dose-Response Relationship, Drug
  • Drug Therapy / standards
  • Drug-Eluting Stents / standards*
  • Humans
  • Injections, Intra-Arterial / standards
  • Internationality
  • Irinotecan
  • Liver Neoplasms / secondary*
  • Liver Neoplasms / therapy*
  • Practice Guidelines as Topic

Substances

  • Delayed-Action Preparations
  • Irinotecan
  • Camptothecin